Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
2024年5月7日 - 9:00PM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a biopharmaceutical company using advanced cell
engineering technology to develop transformational new medicines,
today announced that Elizabeth Belcher will present a poster at the
27th Annual Meeting of the American Society of Gene & Cell
Therapy.
Allogeneic cell therapies derived from induced
pluripotent stem cells (iPSCs) can greatly reduce the manufacturing
complexities of autologous and donor-derived allogeneic cell
therapies such as scalability, batch-to-batch consistency, and
cost. However, host immune cell recognition and clearance of
exogenous cells can lead to iatrogenic toxicities and ineffective
therapeutic responses. We previously reported generation of iPSCs
using an mRNA-based process that avoids the genomic integration and
instability risks of DNA and viral reprogramming methods. Here, we
report the development of an mRNA-engineered iPSC line developed
using UltraSlice™ to express a B2M-HLA-E fusion transgene in lieu
of the endogenous B2M gene product to mimic native B2M expression
(i.e., upregulation when exposed to proinflammatory stimuli). These
cells may prove useful for the rapid development of therapeutics
with the potential for increased efficacy and safety owing to the
immune-evasive nature of the cells.
"It's exciting to see the continued advancements in
our science and the capabilities of the UltraSlice™ platform," said
Sanjeev Luther, CEO of Eterna Therapeutics. "We look forward to
further exploring the potential clinical applications internally
and with strategic partners."
Poster Presentation Details
Title: Targeted Insertion of HLA-E at the B2M Locus
of mRNA-Reprogrammed iPSCs Facilitates the Development of
Allogeneic Cell Therapies with Enhanced Safety Features
Presenter: Elizabeth Belcher, Research Associate
II
Date: Friday, May 10, 2024
Time: 12:00 Noon
Session Title: Friday Posters Targeted Gene
Insertion
Session Room: Exhibit Hall
Location: Baltimore Convention Center in Baltimore,
MD
About Eterna Therapeutics Inc.
Eterna Therapeutics is a life science company
committed to realizing the potential of mRNA cell engineering to
provide patients with transformational new medicines. Eterna has
in-licensed a portfolio of over 100 patents covering key mRNA cell
engineering technologies, including technologies for mRNA cell
reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™
gene-editing proteins, and the ToRNAdo™ mRNA delivery system from
Factor Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are
trademarks of Factor Bioscience. For more information, please visit
www.eternatx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which are intended to be covered by the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are any statements that are not
statements of historical fact and may be identified by terminology
such as “believe,” “could,” “estimate,” “anticipate,” “expect,”
“plan,” “possible,” “potential,” “project,” “will” or other similar
words and the negatives of such words. Forward-looking statements
are based on current beliefs and assumptions that are subject to
risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
stated or implied in any forward-looking statement as a result of
various factors, including, but not limited to, uncertainties
related to: (i) the evolution of Eterna’s business model into a
platform company focused on mRNA, iPS cell and gene editing
technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna ’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Investor Relations Contact:
investors@eternatx.com
Eterna Therapeutics (NASDAQ:ERNA)
過去 株価チャート
から 9 2024 まで 10 2024
Eterna Therapeutics (NASDAQ:ERNA)
過去 株価チャート
から 10 2023 まで 10 2024